Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, spoke about her health plan’s requirements on quality measures and whether they resonate what CMS requires providers to submit.
Jennifer Malin, MD, staff vice president, Clinical Strategy, Anthem, spoke about her health plan’s requirements on quality measures and whether they resonate what CMS requires providers to submit.
“What we have been focusing on and reports that we’re going to be providing to practices include adherence to our pathways as well as [emergency department] utilization and hospitalizations during treatment and access to hospice and other end-of-life care,” Dr Malin said. She added that these measures are a part of what CMS requires through the Oncology Care Model.
However, for Dr Malin, she sees challenges with developing a small set of more meaningful measures that can be used across their entire network. The crux is to derive maximum information without placing further burden on the practices. She said that Anthem has been working to find a “sweet spot of measures” to help practices compare themselves with other practices across the health plan’s network.
Dr Malin said that America’s Health Insurance Plans, or AHIP, has a work group that has brought together private payers and CMS, which “led to the short list of measures that's included in the current oncology care model.” The challenge, however, remains the lack of standardization across practices, with respect to the data systems used. She went on to add that with pay-for-performance and accountability, the National Quality Forum would ultimately ensure that a said measure is up to par—so that’s the least of her concerns.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More